VORs (Very High Frequency Omni-Directional Range) are ground-based radio navigation aids that historically guided aircraft by transmitting signals allowing pilots to determine their bearing from the ...

The average one-year price target for Vor Biopharma (NasdaqGS:VOR) has been revised to $47.68 / share. This is an increase of ...

Fintel reports that on October 15, 2025, Baird upgraded their outlook for Vor Biopharma (NasdaqGS:VOR) from Neutral to Outperform. Analyst Price Forecast Suggests 18.35% Upside As of September 30, ...

Vor Bio granted Dr. Qing Zuraw stock options and RSUs as part of her employment package, effective July 17, 2025. Vor Bio, a biotechnology company focused on treating autoimmune diseases, announced ...

Vor Bio grants CEO Jean-Paul Kress an option to purchase 83.3 million shares at $0.89, vesting over four years. Vor Bio, a biotechnology company specializing in autoimmune disease treatments, ...

Vor Biopharma Inc. (NYSE:VOR – Free Report) – Equities research analysts at Wedbush issued their Q1 2026 earnings estimates for Vor Biopharma in a research report issued on Thursday, May 8th. Wedbush ...

Vor Biopharma, a cancer cell therapy developer that laid off nearly all of its employees in a wind down of operations last month, has reemerged with new management, an in-licensed lead drug candidate, ...

We can readily understand why investors are attracted to unprofitable companies. Indeed, Vor Biopharma (NASDAQ:VOR) stock is up 116% in the last year, providing strong gains for shareholders.